within Pharmacolibrary.Drugs.ATC.V;

model V10XA02
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 2.7000000000000002e-05,
    adminDuration  = 600,
    adminMass      = 3700 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.36,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.214,
    k12             = 34.5,
    k21             = 34.5
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V10XA02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Iobenguane (131I), also known as 131I-MIBG (metaiodobenzylguanidine), is a radiopharmaceutical agent used for the diagnosis and treatment of certain neuroendocrine tumors, including pheochromocytoma, paraganglioma, and neuroblastoma. It is approved for therapeutic use, with the radioactive iodine isotope (131I) allowing for targeted radiotherapy of tumor cells that uptake norepinephrine analogs.</p><h4>Pharmacokinetics</h4><p>PK parameters reported for adults with neuroendocrine tumors following intravenous administration of therapeutic doses.</p><h4>References</h4><ol><li><p>Casáns-Tormo, I, et al., &amp; Ruano-Pérez, R (2019). Cardiac sympathetic innervation scintigraphy with . <i>Revista espanola de medicina nuclear e imagen molecular</i> 38(4) 262–271. DOI:<a href=\"https://doi.org/10.1016/j.remn.2019.01.001\">10.1016/j.remn.2019.01.001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31031167/\">https://pubmed.ncbi.nlm.nih.gov/31031167</a></p></li><li><p>Kline, RC, et al., &amp; Beierwaltes, WH (1981). Myocardial imaging in man with I-123 meta-iodobenzylguanidine. <i>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</i> 22(2) 129–132. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7463156/\">https://pubmed.ncbi.nlm.nih.gov/7463156</a></p></li><li><p>Défachelles, AS, et al., &amp; Carpentier, P (2011). [Radio iodized metaiodobenzylguanidine (MIBG) in the treatment of neuroblastoma: modalities and indications]. <i>Bulletin du cancer</i> 98(5) 559–569. DOI:<a href=\"https://doi.org/10.1684/bdc.2011.1353\">10.1684/bdc.2011.1353</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21609890/\">https://pubmed.ncbi.nlm.nih.gov/21609890</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V10XA02;
